Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $145
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a Buy rating on DexCom (NASDAQ:DXCM) and raises the price target from $144 to $145.
April 26, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating on DexCom and raises the price target from $144 to $145.
The increase in price target by Canaccord Genuity suggests a positive outlook on DexCom's stock, likely due to strong performance or favorable market conditions. This endorsement from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100